Drug Profile
Dutasteride - GSK
Alternative Names: Avodart; Avolve; Duagen; GG 745; GI 198745; GI-198745X; ZagalloLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GlaxoSmithKline; GSK
- Class Antiandrogens; Antineoplastics; Azasteroids; Eye disorder therapies; Skin disorder therapies; Small molecules
- Mechanism of Action Cholestenone 5-alpha reductase inhibitors; Testosterone antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Alopecia; Benign prostatic hyperplasia
- Phase II Prostate cancer
- Preregistration Submission Withdrawal Prostatic intraepithelial neoplasia
Most Recent Events
- 14 Apr 2021 Discontinued - Phase-III for Alopecia in Peru, Philippines, Russia, Thailand, Mexico, Argentina (PO)
- 14 Apr 2021 Discontinued - Phase-III for Alopecia in Chile (PO)
- 14 Apr 2021 Discontinued - Phase-III for Alopecia in Hong Kong (PO)